Licensing and Commercialization Agreements (Details) - USD ($) $ in Thousands	1 Months Ended						3 Months Ended			6 Months Ended		22 Months Ended
	Aug. 31, 2017	Jul. 31, 2017	Jun. 30, 2016	Mar. 31, 2015	Sep. 30, 2014	May 31, 2014	Jun. 30, 2018	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront fees received	$ 16,900
Total collaboration revenue							$ 0	$ 206,700	$ 1,661	$ 0	$ 3,323
License revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaboration revenue							0		0	0	0
Research and development activity revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaboration revenue							0		1,658	0	3,316
API transfer revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaboration revenue							0		0	0	0
Joint operating committee revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Total collaboration revenue							$ 0		$ 3	$ 0	$ 7
Licensing and Commercialization Agreement | Novartis Pharma AG
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront fees received		$ 189,800				$ 200,000
Licensing and Commercialization Agreement | Novartis Pharma AG | Achievement of specified patient enrollment milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Patient enrollment-based milestone revenue achieved			$ 30,000	$ 50,000	$ 50,000							$ 130,000